Tumoricidal activity of combining the agonistic DR5 antibody D-6 with cisplatin in C30 cisplatin‑resistant ovarian cancer in vitro and in vivo

Huang,Yan; Liang,Baoquan; Jiang,Qin; Chen,Chen; Yang,Kun; Li,Chunmei; Zheng,Ai

doi:10.3892/mmr.2014.2193

Tumoricidal activity of combining the agonistic DR5 antibody D-6 with cisplatin in C30 cisplatin‑resistant ovarian cancer in vitro and in vivo

Authors:
- Yan Huang
- Baoquan Liang
- Qin Jiang
- Chen Chen
- Kun Yang
- Chunmei Li
- Ai Zheng
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: April 28, 2014 https://doi.org/10.3892/mmr.2014.2193
Pages: 183-190

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A previous study by our group reported that the agonistic DR5 antibody D-6 was capable of triggering apoptosis in A2780 cisplatin-sensitive ovarian cancer cells and that this marked effect was enhanced by cisplatin in vitro. The present study examined whether D-6 and cisplatin may exert the same anti-tumor effect on C30 cisplatin-resistant ovarian cancer cells, and the underlying mechanisms were investigated. D-6 exhibited an apoptosis-inducing effect, increased the cell growth inhibition rate of C30 cells in a dose-dependent manner, induced significant morphological changes characteristic for apoptosis, as observed by electron microscopy, and downregulated the expression of caspase 3, 8 and 9 precursors in C30 cells treated with D-6 at the protein level. All of these effects were evidently enhanced when accompanied by cisplatin. Furthermore, D-6 alone or in combination with cisplatin in the established models of C30 tumor xenografts resulted in a significant repression of tumor growth, and evident apoptosis, as determined by a terminal transferase dUTP nick end labeling assay. In addition, the expression of caspase 3, 8 and 9 precursors in the tumor xenografts was as similar to that found in vitro. In conclusion, the present study suggested that D-6 may serve as a novel anti-tumor agent against C30 cisplatin‑resistant ovarian cancer, with the ability to trigger apoptosis via caspase-dependent and ‑independent pathways and the potential to decrease the cisplatin resistance of the C30 cell line.

View Figures

View References

1	Fialka I, Pasquali C, Kurzbauer R, Lottspeich F and Huber LA: Loss of epithelial polarity is accompanied by differential association of proteins with intracellular membranes. Electrophoresis. 20:331–343. 1999. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3	Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 271:12687–12690. 1996. View Article : Google Scholar : PubMed/NCBI
4	Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673–682. 1995. View Article : Google Scholar : PubMed/NCBI
5	Lacour S, Hammann A, Wotawa A, Corcos L, Solary E and Dimanche-Boitrel MT: Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 61:1645–1651. 2001.
6	Ma Y, Yang D and Chen Y: Analysis of TRAIL receptor expression using anti-TRAIL death receptor-5 monoclonal antibodies. Chin Med J (Engl). 116:947–950. 2003.PubMed/NCBI
7	Jo M, Kim TH, Seol DW, et al: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med. 6:564–567. 2000. View Article : Google Scholar : PubMed/NCBI
8	Nitsch R, Bechmann I, Deisz RA, et al: Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet. 356:827–828. 2000. View Article : Google Scholar : PubMed/NCBI
9	Jiang Q, Zhu H, Liang B, Huang Y and Li C: Apoptosis-inducing effect of the DR5 monoclonal antibody, D-6, alone or in combination with cisplatin, on A2780 ovarian cancer cells. Mol Med Rep. 6:316–320. 2012.PubMed/NCBI
10	Guo Y, Chen C, Zheng Y, et al: A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death. J Biol Chem. 280:41940–41952. 2005. View Article : Google Scholar : PubMed/NCBI
11	Yagita H, Takeda K, Hayakawa Y, Smyth MJ and Okumura K: TRAIL and its receptors as targets for cancer therapy. Cancer Sci. 95:777–783. 2004. View Article : Google Scholar : PubMed/NCBI
12	Pukac L, Kanakaraj P, Humphreys R, et al: HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer. 92:1430–1441. 2005. View Article : Google Scholar : PubMed/NCBI
13	Gibson SB, Oyer R, Spalding AC, Anderson SM and Johnson GL: Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 20:205–212. 2000. View Article : Google Scholar : PubMed/NCBI
14	Wu GS, Burns TF, McDonald ER III, et al: KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI
15	Sheikh MS, Burns TF, Huang Y, et al: p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 58:1593–1598. 1998.PubMed/NCBI
16	Rajeshkumar NV, Rasheed ZA, García-García E, et al: A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther. 9:2582–2592. 2010. View Article : Google Scholar
17	Er E, Oliver L, Cartron PF, Juin P, Manon S and Vallette FM: Mitochondria as the target of the pro-apoptotic protein Bax. Biochim Biophys Acta. 1757:1301–1311. 2006. View Article : Google Scholar : PubMed/NCBI
18	Bevis KS, McNally LR, Sellers JC, et al: Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol. 121:193–199. 2011. View Article : Google Scholar : PubMed/NCBI
19	Li W, Wang S, Chen C and Zhuang G: Induction of tumor cell apoptosis via Fas/DR5. Cell Mol Immunol. 3:467–471. 2006.PubMed/NCBI
20	Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R and Zhou T: Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene. 22:2034–2044. 2003. View Article : Google Scholar : PubMed/NCBI
21	Ohtsuka T and Zhou T: Bisindolylmaleimide VIII enhances DR5-mediated apoptosis through the MKK4/JNK/p38 kinase and the mitochondrial pathways. J Biol Chem. 277:29294–29303. 2002. View Article : Google Scholar : PubMed/NCBI
22	Estes JM, Oliver PG, Straughn JM Jr, et al: Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol. 105:291–298. 2007. View Article : Google Scholar : PubMed/NCBI
23	Kang Z, Chen JJ, Yu Y, et al: Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of response. Clin Cancer Res. 17:3181–3192. 2011. View Article : Google Scholar : PubMed/NCBI
24	Yada A, Yazawa M, Ishida S, et al: A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol. 19:1060–1067. 2008. View Article : Google Scholar : PubMed/NCBI
25	Jin H, Yang R, Ross J, et al: Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. 14:7733–7740. 2008. View Article : Google Scholar : PubMed/NCBI
26	Straughn JM Jr, Oliver PG, Zhou T, et al: Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol Oncol. 101:46–54. 2006. View Article : Google Scholar : PubMed/NCBI
27	Kaplan-Lefko PJ, Graves JD, Zoog SJ, et al: Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 9:618–631. 2010. View Article : Google Scholar : PubMed/NCBI
28	Kindler HL, Richards DA, Garbo LE, et al: A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol. 23:2834–2842. 2012. View Article : Google Scholar : PubMed/NCBI
29	Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J and Hood L: Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 7:821–830. 1997. View Article : Google Scholar : PubMed/NCBI
30	Buchsbaum DJ, Zhou T, Grizzle WE, et al: Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res. 9:3731–3741. 2003.PubMed/NCBI